Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 12/20 | 0.44 |
| ▸ | GIPR | P48546 | 5/20 | 0.43 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | GCG | P01275 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651414 | 0.89 | GCGR (0.46) | GCGRGIPRGLP1RPPARDGCG | |
| SCHEMBL4091344 | 0.88 | GCGR (0.45) | GCGRGIPRGLP1RPPARDGCG | |
| SCHEMBL2651279 | 0.87 | GCGR (0.48) | GCGRGIPREPHX2 | |
| SCHEMBL2651304 | 0.87 | GCGR (0.48) | GCGRGIPRGLP1RPPARDGCG | |
| SCHEMBL2661778 | 0.85 | GCG (0.49) | GCGRGIPRGLP1RGCGEPHX2 | |
| SCHEMBL2653167 | 0.84 | GCGR (0.46) | GCGRGIPRGLP1RGCGEPHX2 | |
| SCHEMBL2650910 | 0.83 | HDAC8 (0.47) | GCGRGIPRGLP1RPPARDGCG | |
| SCHEMBL4096042 | 0.82 | GCGR (0.49) | GCGRGIPRGLP1REPHX2 | |
| SCHEMBL4081733 | 0.82 | EPHX2 (0.45) | GCGRGIPRPPARDGCGEPHX2 | |
| SCHEMBL4087091 | 0.82 | GCGR (0.52) | GCGRGIPRGLP1RPPARDGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | MADSEN PETER (DK) | 2004-07-01 | — | — | US | claimed |
| US-6706744-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2004-03-16 | — | — | US | claimed |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-04-03 | — | — | US | claimed |
| WO-2002040444-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | claimed |
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | MADSEN PETER (DK) | 2004-07-01 | — | — | US | disclosed |
| US-6706744-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2004-03-16 | — | — | US | disclosed |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-04-03 | — | — | US | disclosed |
| WO-2002040444-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.